Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Drug-Drug Interaction Study of Lasmiditan
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Eli Lilly
- 05 Mar 2018 Status changed from recruiting to completed.
- 18 Aug 2017 Status changed from not yet recruiting to recruiting.
- 18 Aug 2017 New trial record